- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07945275
A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients
A Randomized Superiority Study Comparing Model-Guided Optimized Dosing With Empirical Dosing of Piperacillin/Tazobactam in Elderly Patients With Community-Acquired Pneumonia
This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.
Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.
But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.
The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.
Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.
Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Wei Zhao
- Telefonnummer: +8653188383308
- E-post: zhao4wei2@hotmail.com
Studiesteder
-
-
Shandong
-
Jinan, Shandong, Kina, 250000
- Rekruttering
- Shandong Provincial Public Health Clinical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥ 65 years;
- Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:
Onset in the community setting;
At least one of the following clinical manifestations:
New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or < 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion.
For patients aged ≥ 65 years with a body temperature < 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria.
- At least one of the following risk factors for drug-resistant pathogens:
Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility;
- Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment.
- Expected length of hospital stay ≥ 72 hours;
- Signed informed consent form.
Exclusion Criteria:
- Highly suspected or confirmed fungal pneumonia or viral pneumonia;
- Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others;
- Patients with severe allergy to β-lactams and history of severe adverse reactions;
- End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure;
- Severe renal insufficiency with creatinine clearance <40 mL/min, or patients receiving continuous renal replacement therapy (CRRT);
- Any other conditions deemed ineligible for enrollment by investigators.
Post-randomization exclusion criteria:
- Isolated fungal infection;
- Isolated viral infection;
- Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: guideline-based conventional dosing
|
Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days. |
|
Eksperimentell: Model-guided optimized dosing
|
Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The proportion of patients achieving the predefined pharmacodynamic (PD) target.
Tidsramme: up to 1 month
|
up to 1 month
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Clinical improvement rate after 3 days of empiric therapy
Tidsramme: Day 3
|
Day 3
|
|
Length of hospital stay
Tidsramme: through hospital discharge, an average of 2 weeks
|
through hospital discharge, an average of 2 weeks
|
|
Treatment success rate
Tidsramme: through hospital discharge, an average of 4 weeks
|
through hospital discharge, an average of 4 weeks
|
|
Adverse event (AE) incidence rate
Tidsramme: through end of study-drug treatment, an average of 7 days
|
through end of study-drug treatment, an average of 7 days
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Luftveisinfeksjoner
- Infeksjoner
- Sykdommer i luftveiene
- Lungesykdommer
- Lungebetennelse
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Terapeutikk
- Drug Administration -ruter
- Medikamentell terapi
- Amides
- Penicillin g
- Beta-laktams
- Laktams
- Sulfoner
- Penikillansyre
- Ampicillin
- Penicillins
- Tazobaktam
- Piperacillin
- Injeksjoner
Andre studie-ID-numre
- SDU-2026-elePIP-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data (IPD) will not be shared due to patient privacy and confidentiality regulations, and the lack of specific informed consent for public data sharing.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .